Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) FCF Margin (2016 - 2025)

Historic FCF Margin for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to 4.29%.

  • Arrowhead Pharmaceuticals' FCF Margin rose 61558100.0% to 4.29% in Q4 2025 from the same period last year, while for Dec 2025 it was 29.51%, marking a year-over-year increase of 228939900.0%. This contributed to the annual value of 18.91% for FY2025, which is 170372200.0% up from last year.
  • Arrowhead Pharmaceuticals' FCF Margin amounted to 4.29% in Q4 2025, which was up 61558100.0% from 5.06% recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' FCF Margin ranged from a high of 782.38% in Q1 2021 and a low of 6151.52% during Q4 2024
  • Moreover, its 5-year median value for FCF Margin was 182.95% (2022), whereas its average is 778.08%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -50689800bps in 2023, then skyrocketed by 61558100bps in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' FCF Margin (Quarter) stood at 244.49% in 2021, then increased by 25bps to 182.95% in 2022, then tumbled by -2771bps to 5251.93% in 2023, then fell by -17bps to 6151.52% in 2024, then surged by 100bps to 4.29% in 2025.
  • Its FCF Margin was 4.29% in Q4 2025, compared to 5.06% in Q3 2025 and 565.72% in Q2 2025.